All In Biotech

Drug Trial Radar · NCT06716970

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

A Multicenter, Randomized, Double-blind, and Active-controlled Parallel Study to Evaluate the Efficacy and Safety of QR12000 Compound Tablets and Sacubitril/valsartan Tablets in Patients with Moderate to Severe Essential Hypertension

Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 810 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

810

Planned (sponsor's estimate)

Start

Dec 30, 2024

Primary completion

Apr 30, 2026

Study completion Feb 28, 2027

Sponsor

Sponsor type
Industry
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.

Conditions

  • Essential Hypertension

Interventions

  • QR12000 75mgDrug

    QR12000 75mg QD

  • QR12000 75mg placeboDrug

    Matching placebo of QR12000 75mg QD

  • QR12000 150mgDrug

    QR12000 150mg QD

  • QR12000 150mg placeboDrug

    Matching placebo of QR12000 150mg QD

  • Sacubitril/valsartan 200mgDrug

    Sacubitril/valsartan 200mg QD

  • Sacubitril/valsartan 200mg placeboDrug

    Matching placebo of Sacubitril/valsartan 200mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)Time frame: Baseline and week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.